# A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

> **NCT03818256** · PHASE2 · COMPLETED · sponsor: **Corcept Therapeutics** · enrollment: 71 (actual)

## Conditions studied

- Antipsychotic-induced Weight Gain (AIWG)

## Interventions

- **DRUG:** Miricorilant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03818256
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-04
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-07-06
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03818256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03818256, "A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03818256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*